Search Results - "TAUER, K. W"

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer by West, W H, Tauer, K W, Yannelli, J R, Marshall, G D, Orr, D W, Thurman, G B, Oldham, R K

“…Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but…”
Get more information

High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast by SCHWARTZBERG, L. S, WEAVER, C. H, LEWKOW, L, MCANENY, B, ZHEN, B, BIRCH, R, WEST, W. H, TAUER, K. W, BUCKNER, C. D

“…The purpose of this study was to determine outcomes for 56 patients with inflammatory breast cancer (IBC) receiving high-dose chemotherapy (HDC) with…”
Get full text

Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial by Dillman, R O, Oldham, R K, Tauer, K W, Orr, D W, Barth, N M, Blumenschein, G, Arnold, J, Birch, R, West, W H

“…We conducted a multicenter, phase II trial of continuous-infusion recombinant interleukin-2 (rIL-2) and lymphokine-activated killer (LAK) cells. Patients had…”
Get more information

Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: Outpatient administration in community cancer centers by SCHWARTZBERG, L. S, BIRCH, R, GRECO, F. A, HAINSWORTH, J, RAEFSKY, E, BLANCO, R, BUCKNER, C. D, WEAVER, C. H, WEST, W. H, TAUER, K. W, WITTLIN, F, LEFF, R, CAMPOS, L, RYMER, W, CARTER, P, MANGUM, M

“…The authors determined outcomes for patients with localized high-risk breast cancer undergoing sequential outpatient treatment with conventional-dose adjuvant…”
Get full text

Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes by SCHWARTZBERG, L. S, BIRCH, R, BUCKNER, C. D, WEAVER, C. H, TAUER, K. W, LEFF, R, GRECO, F. A, HAINSWORTH, J, RAEFSKY, E, MCANENY, B, WEAVER, Z, WEST, J

“…The purpose of this study is to determine outcomes for patients with high-risk nonmetastatic breast cancer undergoing high-dose chemotherapy with peripheral…”
Get full text

LAK cell therapy--clinical studies and future potential by Marshall, Jr, G D, Schwartzberg, L S, Tauer, K W, Lee, P, Holbert, Jr, J M, West, W H

Get more information

Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV) by Hudis, C., Tauer, K. W., Hermann, R. C., Makari-Judson, G., Isaacs, C., Beck, J. T., Kaklamani, V. G., Stepanski, E. J., Rugo, H. S., Wang, W., Bell-McGuinn, K. M., Chera, H., Zaugg, B., Ro, S. K., Li, S., Schwartzberg, L. S.

“…Abstract only…”
Get full text

The impact of anemia treatment visits on the patient and their caregiver by Tauer, K. W., Zhu, L., Fortner, B. V.

“…Abstract only…”
Get full text

The impact of anemia treatment visits on the patient and their caregiver by Tauer, K. W., Zhu, L., Fortner, B. V.

“…Abstract only…”
Get full text

Final results of the National Patient Impact Initiative by Tauer, K. W., Fortner, B. V., Zhu, L., Ma, L., Schwartzberg, L. S.

“…Abstract only…”
Get full text

Abstract P5-20-08: Phase II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC) by Schwartzberg, LS, Tauer, KW, Schnell, FM, Hermann, R, Rubin, P, Christianson, D, Weinstein, P, Epperson, A, Walker, M

“…Abstract Background: Ixa is a novel semi-synthetic epothilone microtubule blocking agent with activity in taxane and anthracycline-resistant MBC. D is a potent…”
Get full text

Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma by West, W H, Tauer, K W, Yannelli, J R, Marshall, G D, Orr, D, Lewis, M, Birch, R, Oldham, R K

“…Twenty patients were treated with metastatic renal cell cancer with 5-day cycles of constant infusion recombinant interleukin-2 (rIL-2) at 3 X 10(6) U/m2/day…”
Get more information

Abstract P6-12-08: Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) +/− Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC) by Schwartzberg, LS, Hermann, R, Blakely, J, Richey, SS, Tauer, KW, Childs, BH

“…Abstract Background: The addition of Bev to the taxanes docetaxel and paclitaxel has resulted in improved progression-free survival (PFS) in the first line…”
Get full text

Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor by Schwartzberg, L S, Birch, R, Hazelton, B, Tauer, K W, Lee, Jr, P, Altemose, R, George, C, Blanco, R, Wittlin, F, Cohen, J

“…Chemotherapy can serve as a stimulus for mobilizing hematopoietic progenitor cells to the peripheral blood for harvest via leukapheresis. Mobilized peripheral…”
Get more information